Intravenous immunoglobulin treatment for chronic inflammatory demyelinating polyneuropathy usually starts with a 2.0 g/kg induction dose followed by 1.0 g/kg maintenance doses every 3 weeks. No dose-ranging studies with intravenous immunoglobulin maintenance therapy have been published. The Progress in Chronic Inflammatory Demyelinating polyneuropathy (ProCID) study was a prospective, double-blind, randomized, parallel-group, multicentre, phase III study investigating the efficacy and safety of 10% liquid intravenous immunoglobulin (Panzyga®) in patients with active chronic inflammatory demyelinating polyneuropathy. Patients were randomized 1:2:1 to receive the standard intravenous immunoglobulin induction dose and then either 0.5, 1.0 or 2.0 g/kg maintenance doses every 3 weeks. The primary end point was the response rate in the 1.0 g/kg group, defined as an improvement ≥1 point in adjusted Inflammatory Neuropathy Cause and Treatment score at Week 6 versus baseline and maintained at Week 24. Secondary end points included dose response and safety. This trial was registered with EudraCT (Number 2015-005443-14) and clinicaltrials.gov (NCT02638207). Between August 2017 and September 2019, the study enrolled 142 patients. All 142 were included in the safety analyses. As no post-infusion data were available for three patients, 139 were included in the efficacy analyses, of whom 121 were previously on corticosteroids. The response rate was 80% (55/69 patients) [95% confidence interval (CI): 69-88%] in the 1.0 g/kg group, 65% (22/34; CI: 48-79%) in the 0.5 g/kg group, and 92% (33/36; CI: 78-97%) in the 2.0 g/kg group. While the proportion of responders was higher with higher maintenance doses, logistic regression analysis showed that the effect on response rate was driven by a significant difference between the 0.5 and 2.0 g/kg groups, whereas the response rates in the 0.5 and 2.0 g/kg groups did not differ significantly from the 1.0 g/kg group. Fifty-six per cent of all patients had an adjusted Inflammatory Neuropathy Cause and Treatment score improvement 3 weeks after the induction dose alone. Treatment-related adverse events were reported in 16 (45.7%), 32 (46.4%) and 20 (52.6%) patients in the 0.5, 1.0 and 2.0 g/kg dose groups, respectively. The most common adverse reaction was headache. There were no treatment-related deaths. Intravenous immunoglobulin (1.0 g/kg) was efficacious and well tolerated as maintenance treatment for patients with chronic inflammatory demyelinating polyneuropathy. Further studies of different maintenance doses of intravenous immunoglobulin in chronic inflammatory demyelinating polyneuropathy are warranted.

Brain and Mind Center University of Sydney Sydney NSW 2050 Australia

Clinical R and D Octapharma PPG Vienna 1100 Austria

Curaçao Medical Center Willemstad Curaçao

Department of Neurology Erasmus University Medical Center Rotterdam 3015CE The Netherlands

Department of Neurology Heinrich Heine University Düsseldorf 40225 Germany

Department of Neurology Johns Hopkins University Baltimore MD 21287 USA

Department of Neurology Maastricht University Medical Center Maastricht 6229 HX The Netherlands

Department of Neurology Medical University of Vienna Vienna 1090 Austria

Department of Neurology Palacky University Olomouc 771 47 Czech Republic

Department of Neurology University of Toronto Toronto M5G 2C4 Canada

Zobrazit více v PubMed

van den Bergh PYK, Hadden RDM, Bouche P, et al. ; Peripheral Nerve Society. European Federation of Neurological Societies/Peripheral Nerve Society guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy: Report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society - first revision. Eur J Neurol. 2010;17(3):356–363. PubMed

van den Bergh PYK, van Doorn PA, Hadden RDM, et al. . European Academy of Neurology/Peripheral Nerve Society Guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy: Report of a joint Task Force - second revision. J Peripher Nerv Syst. 2021;26(3):242–268. PubMed

Allen JA, Lewis RA. CIDP diagnostic pitfalls and perception of treatment benefit. Neurology. 2015;85(6):498–504. PubMed

Neligan A, Reilly MM, Lunn MP. CIDP: Mimics and chameleons. Pract Neurol. 2014;14(6):399–408. PubMed

Oaklander AL, Lunn MP, Hughes RA, van Schaik IN, Frost C, Chalk CH. Treatments for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP): An overview of systematic reviews. Cochrane Database Syst Rev. 2017;1:CD010369. PubMed PMC

Hughes RAC, Donofrio P, Bril V, et al. ; ICE Study Group. Intravenous immune globulin (10% caprylate-chromatography purified) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE study): A randomised placebo-controlled trial. Lancet Neurol. 2008;7(2):136–144. PubMed

Léger J-M, Bleecker JL, de Sommer C, et al. ; PRIMA study investigators. Efficacy and safety of Privigen® in patients with chronic inflammatory demyelinating polyneuropathy: Results of a prospective, single-arm, open-label Phase III study (the PRIMA study). J Peripher Nerv Syst. 2013;18(2):130–140. PubMed PMC

Nobile‐Orazio E, Pujol S, Kasiborski F, et al. . An international multicenter efficacy and safety study of IqYmune in initial and maintenance treatment of patients with chronic inflammatory demyelinating polyradiculoneuropathy: PRISM study. J Peripher Nerv Syst. 2020;25(4):356–365. PubMed PMC

Rajabally YA, Seow H, Wilson P. Dose of intravenous immunoglobulins in chronic inflammatory demyelinating polyneuropathy. J Peripher Nerv Syst. 2006;11(4):325–329. PubMed

Rajabally YA, Afzal S. Clinical and economic comparison of an individualised immunoglobulin protocol vs. standard dosing for chronic inflammatory demyelinating polyneuropathy. J Neurol. 2019;266(2):461–467. PubMed PMC

Kuitwaard K, Fokkink W-JR, Brusse E, et al. . Maintenance IV immunoglobulin treatment in chronic inflammatory demyelinating polyradiculoneuropathy. J Peripher Nerv Syst. 2017;22(4):425–432. PubMed

Lunn MP, Ellis L, Hadden RD, Rajabally YA, Winer JB, Reilly MM. A proposed dosing algorithm for the individualized dosing of human immunoglobulin in chronic inflammatory neuropathies. J Peripher Nerv Syst. 2016;21(1):33–37. PubMed

Kubori T, Mezaki T, Kaji R, et al. . The clinical usefulness of high-dose intravenous immunoglobulin therapy for chronic inflammatory demyelinating polyneuropathy and multifocal motor neuropathy. No to Shinkei. 1999;51(2):127–135. PubMed

van Schaik IN, Bril V, van Geloven N, et al. ; PATH study group. Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (PATH): A randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurol. 2018;17(1):35–46. PubMed

Mersich C, Ahrer K, Buchacher A, et al. . Biochemical characterization and stability of immune globulin intravenous 10% liquid (Panzyga®). Biologicals. 2017;45:33–38. PubMed

Radomski KU, Lattner G, Schmidt T, Römisch J. Pathogen safety of a new intravenous immune globulin 10% liquid. BioDrugs. 2017;31(2):125–134. PubMed PMC

Borte M, Melamed IR, Pulka G, et al. . Efficacy and safety of human intravenous immunoglobulin 10% (Panzyga®) in patients with primary immunodeficiency diseases: A two-stage, multicenter, prospective, open-label study. J Clin Immunol. 2017;37(6):603–612. PubMed PMC

Arbach O, Taumberger AB, Wietek S, Cervinek L, Salama A. Efficacy and safety of a new intravenous immunoglobulin (Panzyga®) in chronic immune thrombocytopenia. Transfus Med. 2019;29(1):48–54. PubMed PMC

panzyga® USPI. 2021. https://www.fda.gov/media/115397/download. Accessed 16 July 2021.

panzyga® Canadian Product Monograph. 2017. https://pdf.hres.ca/dpd_pm/00041520.PDF. Accessed 16 July 2021.

panzyga® SmPC. 2019. https://www.medicines.org.uk/emc/product/7317/smpc#gref. Accessed 16 July 2021.

Cornblath DR, Hartung H-P, Katzberg HD, Merkies ISJ, van Doorn PA. A randomised, multi-centre phase III study of 3 different doses of intravenous immunoglobulin 10% in patients with chronic inflammatory demyelinating polyradiculoneuropathy (ProCID trial): Study design and protocol. J Peripher Nerv Syst. 2018;23(2):108–114. PubMed PMC

Draak THP, Vanhoutte EK, van Nes SI, et al. ; PeriNomS Study Group. Changing outcome in inflammatory neuropathies: Rasch-comparative responsiveness. Neurology. 2014;83(23):2124–2132. PubMed

van Schaik IN, Mielke O, Bril V, et al. ; PATH study group. Long-term safety and efficacy of subcutaneous immunoglobulin IgPro20 in CIDP: PATH extension study. Neurol Neuroimmunol Neuroinflamm. 2019;6(5):e590. PubMed PMC

Bunschoten C, Jacobs BC, van den Bergh PYK, Cornblath DR, van Doorn PA. Progress in diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy. Lancet Neurol. 2019;18(8):784–794. PubMed

Hughes RA, Mehndiratta MM, Rajabally YA. Corticosteroids for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database Syst Rev. 2017;11:CD002062. PubMed PMC

Latov N, Deng C, Dalakas MC, et al. ; IGIV-C CIDP Efficacy (ICE) Study Group. Timing and course of clinical response to intravenous immunoglobulin in chronic inflammatory demyelinating polyradiculoneuropathy. Arch Neurol. 2010;67(7):802–807. PubMed

Time for a standardized diagnostic response test in patients with chronic inflammatory demyelinating polyradiculoneuropathy?

Safety and Tolerability of Intravenous Immunoglobulin in Chronic Inflammatory Demyelinating Polyneuropathy: Results of the ProCID Study

Zobrazit více v PubMed

ClinicalTrials.gov
NCT02638207